Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- AbbVie Japan Files Rinvoq for Ankylosing Spondylitis
July 1, 2021
- Taisho Grants Worldwide Rights for Antidepressant TS-121 to US Firm
July 1, 2021
- New BMS Japan Boots Up with Richer Cancer Assets as Celgene Merger Closes
July 1, 2021
- 2 Ono Employees Found Guilty for Onoact Bribery Charges; Scholarship Donation in Spotlight
June 30, 2021
- Chugai Files Regeneron’s Antibody Cocktail in Japan
June 30, 2021
- Japan Top Court Rejects Prosecutors’ Appeal in Diovan Case; Novartis Not Guilty
June 30, 2021
- Takeda CEO Takes Home 1.87 Billion Yen in FY2020
June 30, 2021
- Takeda’s Leuplin Supply Curb Remains More than 1 Year after Measure Set Off
June 29, 2021
- Organon Japan to Focus on Women’s Health, Enrich Offerings with Global Products: President
June 29, 2021
- HIF-PH Med Roxadustat Gets EU Panel Backing: Astellas/FibroGen
June 29, 2021
- Kaken Files Japan NDA for Eschar Remover KMW-1
June 29, 2021
- Kissei Licenses Out South Korean Rights for Fostamatinib
June 29, 2021
- Novo’s Smart Insulin Pens Get Japan Approval, Launch in H1 2022
June 28, 2021
- Otsuka Seeks EU Nod for Lupus Nephritis Drug
June 28, 2021
- CellCept Gets Additional Nod for GVHD in HSCT: Chugai
June 28, 2021
- Sumitomo Dainippon Chief’s Pay Tops 100 Million Yen
June 28, 2021
- MSD Chief Wants Japan to Eliminate Disincentives Tied to Re-Pricing Rules as Keytruda Faces Repeated Cuts
June 28, 2021
- Sawai Expands Shipment Adjustments to 369 Products
June 28, 2021
- Biosimilar Momentum Unabated in Japan Even with Supply Concerns
June 25, 2021
- Japan Pharma Market Forecast to Decline through FY2025: IQVIA
June 25, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…